EP2010208A1 - Amyline et agonistes d'amyline pour traiter les maladies et troubles psychiatriques - Google Patents

Amyline et agonistes d'amyline pour traiter les maladies et troubles psychiatriques

Info

Publication number
EP2010208A1
EP2010208A1 EP06816288A EP06816288A EP2010208A1 EP 2010208 A1 EP2010208 A1 EP 2010208A1 EP 06816288 A EP06816288 A EP 06816288A EP 06816288 A EP06816288 A EP 06816288A EP 2010208 A1 EP2010208 A1 EP 2010208A1
Authority
EP
European Patent Office
Prior art keywords
amylin
seq
xaa
disorder
hamylin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06816288A
Other languages
German (de)
English (en)
Inventor
Kevin D. Laugero
Michael Hanley
Christine Mack
David G. Parkes
Andrew A. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/012601 external-priority patent/WO2006105527A2/fr
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of EP2010208A1 publication Critical patent/EP2010208A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This disclosure is in the medical field and in particular to the fields of psychology and psychiatry, as well as health, diet and nutrition.
  • Psychiatric diseases and disorders are described in resources such as the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, or DSM-W.
  • DSM-W American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders
  • Broad categories of mental disorders include, but are not limited to, mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance-related disorders, sleep disorders, somatoform disorders, and eating disorders.
  • mood disorders include bipolar and depression.
  • Other conditions falling within the broader category of disorders described above can be found in the DSM-IV, which is incorporated by reference in its entirety.
  • Depressive disorders can encompass, among others illnesses, major depressive disorder, dysthymic disorder and bipolar disorder. About 9 to 9.5 percent of the U.S. population ages 18 and older have a depressive condition. It has been reported that the direct _ ⁇ ⁇ cost olMprls-iivk di'slilfes is a ⁇ o ⁇ t $80 billion, with two-thirds of it being borne by businesses. The indirect costs associated with depressive disorders, such as lost productivity, are harder to calculate because of events such as "presenteeism,” described as people at work but limited in their ability to produce or participate (Durso, Employee Benefit News, Dec 2004).
  • anxiety disorders Another psychiatric condition is anxiety disorders. These disorders can include panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder generalized anxiety disorder, and phobias. Approximately 19.1 million American adults ages 18 to 54 (about 13.3% of people in this age group in a given year) have an anxiety disorder.
  • Another common psychiatric condition is eating disorders.
  • eating disorders There are three main types, anorexia nervosa, bulimia nervosa, and binge-eating disorders.
  • These are psychiatric conditions are often linked to perceived notions about body image and are usually independent of actual body weight or body mass index.
  • the mortality of people with anorexia has been estimated at 0.56 percent per year, or approximately 5.6 percent per decade, which is about 12 times higher than the annual death rate due to all causes of death among females ages 15-24 in the general population (Sullivan (1995) American Journal of Psychiatry 152:1073-1074). It should be noted that psychiatric illnesses usually present with elements of other psychiatric disorders.
  • Schizophrenia is a chronic, debilitating disease that leaves an estimated 75% of treated patients without ever achieving complete recovery. Treatment of schizophrenia with the newer (atypical) antipsychotic medications frequently comes with the side effect of weight gain and possibly diabetes.
  • Exemplary types of schizophrenia include paranoid schizophrenia. These persons are very suspicious of others and often have grand schemes of doctrine at the root of their behavior. Hallucinations, and more frequently delusions, are a prominent and common part of the illness. Persons with disorganized schizophrenia (Hebephrenic Schizophrenia) are verbally incoherent and may have moods and emotions that are not appropriate to the situation. Hallucinations are not usually present with disorganized schizophrenia.
  • Catatonic schizophrenia is where a person is extremely withdrawn, negative and isolated, and has marked psychomotor disturbances.
  • Residual schizophrenia is where a person is not currently suffering from delusions, hallucinations, or disorganized speech and behavior, but lacks motivation and interest in day-to-day living.
  • Schizoaffective disorder is where a person has symptoms of schizophrenia as well as mood disorder such as major depression, bipolar mania, or mixed mania.
  • Undifferentiated schizophrenia is where conditions meet the general diagnostic criteria for schizophrenia but do not conform to any of the above lultypes 1' , IbI tlere' i lre 1' felrates -of more than one of the subtypes without a clear predominance of a particular set of diagnostic characteristics.
  • Psychiatric diseases and disorders can be found in any age group. Accordingly, these disorders can be found in young adults and adults (defined herein as those aged 65 or under) as well as infants, children, adolescents, and the elderly (defined herein as over the age of 65). In fact, certain segments of the population may be particularly prone to having a condition, such as eating disorders in adolescents and young adults. The elderly may be particularly susceptible to conditions such as depression.
  • methods provided include the use of amylin and its agonists, analogs, or derivatives in therapeutically effective amounts for the treatment of a psychiatric disorder.
  • the psychiatric disorder is a mood disorder, an anxiety disorder, schizophrenia or other psychotic disorder, a substance-related disorder, a sleep disorder, a somatoform disorder, and/or an eating disorder.
  • the psychiatric disorder is depression or bipolar disorder.
  • the psychiatric disorder is an obsessive- compulsive disorder.
  • methods provided may not include treating an eating disorder. In other embodiments, methods provided may not include treating anorexia.
  • methods provided may not include a somatoform disorder.
  • amylin and its agonists, analogs, or derivatives are used to treat the underlying psychiatric condition of an eating disorder.
  • amylin and its agonists, analogs, or derivatives are used to treat the underlying psychiatric condition of a somatoform disorder.
  • amylin agonists may not include a calcitonin and/or a calcitonin-gene-related peptide ⁇
  • CGRf fJ ⁇ nl ' tili'ytniliMbd ' Jiyi ⁇ ii ⁇ ttylin agonists may not include an analog of calcitonin and/or CGRP.
  • methods provided include treating a psychiatric disorder in a subject desirous of, or in need of, treatment comprising administering a therapeutically effective amount of an amylin, its agonists, analogs, or derivatives to the subject.
  • the subject is overweight.
  • the subject is obese.
  • the subject is lean, not overweight or obese.
  • the subject has a metabolic condition.
  • the subject has diabetes, metabolic syndrome, impaired glucose tolerance, or insulin resistance.
  • amylin and its agonists, analogs, or derivatives are beneficial in aiding the subject with their ability to modify food preferences or food cravings.
  • methods provided herein include administration of a therapeutically effective amount of amylin, or its agonist, analogs, and derivatives, in combination with a conventional treatment for psychiatric disorders.
  • the combination includes the administration of electroconvulsive therapy (ECT).
  • ECT electroconvulsive therapy
  • the combination includes the administration of another psychiatric medication.
  • the psychiatric medication is one or more of tricyclic antidepressants, monamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), herbal antidepressants ⁇ e.g., St John's Wort or Hypericum), or second generation antipsychotic medications (SGAs).
  • MAOIs monamine oxidase inhibitors
  • SSRIs selective serotonin reuptake inhibitors
  • SNRIs serotonin and noradrenaline reuptake inhibitors
  • herbal antidepressants ⁇ e.g., St John's Wort or Hypericum
  • SGAs second generation antipsychotic medications
  • methods provided herein include treating an unwanted side effect of another psychiatric medication comprising administering a therapeutically effective amount of amylin, or its agonist, analogs, and derivatives, to a subject in need thereof.
  • the other psychiatric medication is a second generation antipsychotic medication.
  • the unwanted side effect of the other psychiatric medication is weight gain.
  • the unwanted side effect of the other psychiatric medication is diabetes.
  • methods provided include treating a psychiatric disorder comprising administering a therapeutically effective amount of a compound that modulates behavioral pathways through its modulatory actions on metabolic pathways or function, including but not limited to glucose metabolism, lipid metabolism, protein metabolism, and total energy metabolism.
  • the behavioral pathway is a corticotropin-releasing factor (CRF) pathway that modulates at least one component of the hypothalarnic-pituitary-adrenal axis.
  • the behavioral pathway is a dopamine pathway.
  • the behavioral pathway is the 5HT 1A pathway or any pathway comprising the serotonergic system.
  • the compound is an amylin or its agonist, analog or derivative.
  • methods provided include treating a psychiatric disorder by administering a therapeutically effective amount of a compound that modulates behavioral pathways through its modulatory actions on food intake.
  • the compound is amylin or its agonist, analog or derivative.
  • the disclosure provides for the use of an amylin, its agonists, analogs, or derivatives for manufacture of a medicament useful for treating psychiatric diseases and disorders described herein.
  • the disclosure provides for the use of an amylin, its agonists, analogs, or derivatives for manufacture of a medicament useful for treating unwanted side effects of another psychiatric medication, for example, a second generation antipsychotic medication.
  • Figs. IA and IB are graphs depicting effects of amylin on stress-induced feeding.
  • R indicates animals subjected to restraint stress
  • C indicates control animals not subjected to restraint stress.
  • Fig. 2 is a graph depicting the effect of amylin and control agents on stress-induced hyperthermia in mice.
  • Fig. 3 is a graph depicting the effect of amylin and control agents on marble burying.
  • Fig. 4 is a graph depicting the effect of amylin and vehicle control on animals undergoing the forced swim test.
  • Fig. 5 is a graph depicting the effect of amylin and control agents on prepulse inhibition.
  • Fig. 6 is a graph depicting the effect of amylin and control agents on phencyclidine (PCP)-induced locomotion.
  • Figs. 7A and 7B are graphs depicting effects of clozapine on weight.
  • the graph in Fig. 7A depicts the effect of clozapine alone on weight and the graph in Fig. 7B depicts the effect of the combination of clozapine and amylin on weight.
  • Fig. 8 is a graph depicting the effect of amylin and control agents on novel object recognition. P C TV U S O 6 ,/ 3 B ti ⁇ ftojgD DESCRIPTION
  • amylin, amylin agonists, amylin analogs, amylin agonist analogs, amylin derivatives, or a combination thereof may be able to modulate the stress systems and/or the actions of CRF and/or glucocorticoids (GC), thereby presenting novel pharmacotherapeutic options.
  • GC glucocorticoids
  • amylin administration appears to reduce or protect against stress and it effects (e.g., anxiety, obsessive-compulsive behavior, depression, psychosis, changes in eating behavior).
  • amylin administration results in behavioral effects that include anti-stress, anxiolytic, antidepressant, and antipsychotic actions.
  • the CRF and GC molecules play a critical role in modulating behavioral, neuroendocrine, autonomic, and metabolic function under normal and stressful conditions. Chronic stress and the induction of expression and activity of these molecules are highly associated with behavioral diseases like anxiety and depression, and also with some obesities and diabetes. There is evidence that links CRF and adrenocortical abnormalities to the metabolic syndrome, autoimmune inflammatory disorders, acute and chronic neurodegeneration, sleep disorders, chronic pain, eating disorders, chronic anxiety disorder, and major depression (Wong et al. (2000) Proc. Natl. Acad. Sci. USA 97:325-330; Sarnyai et al. (2001) Pharmacol. Rev. 53:209-243; Heinrichs et al.
  • amylin is shown to share properties of anxiolytic, antidepressant, and antipsychotic agents in behavioral testing.
  • amylin and amylin agonists may have the surprising ability to treat psychiatric disorders.
  • Psychiatric disorders that can be treated include mood disorders, anxiety disorders, schizophrenia ⁇ and otff ⁇ -psycnAI(>slsollefsrs»s ⁇ yee S related disorders, sleep disorders, somatoform disorders, eating disorders, and personality disorders.
  • These compounds may be particularly effective in treating psychiatric disorders that have elements of metabolic disturbances, e.g., eating disorders, or in treating patients with a psychiatric disorder or those with a psychiatric disorder and who also suffer from a metabolic disturbance.
  • psychiatric disorders that have elements of metabolic disturbances, e.g., eating disorders, or in treating patients with a psychiatric disorder or those with a psychiatric disorder and who also suffer from a metabolic disturbance.
  • disorders More particular types of the above named disorders can be found in the DSM-IV.
  • Examples include mood disorders that may include depressive disorders and bipolar disorders. They can further be characterized as major depressive disorders, dysthymic disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, bipolar disorder not otherwise specified, mood disorders due to a medical condition, substance-induced mood disorder, or mood disorder not otherwise specified.
  • Anxiety disorders can include panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, anxiety disorder due to a medical condition, substance induced anxiety disorder and anxiety disorder not otherwise specified.
  • Schizophrenia and other psychotic disorders feature a mixture of generally characteristic signs and symptoms, both positive and negative. Positive symptoms of schizophrenia and other psychotic disorders appear to reflect an excess or distortion of normal functions, whereas the negative symptoms appear to reflect a diminution or loss of normal functions. Positive symptoms include, but are not limited to, delusions, hallucinations, disorganized thinking or thought disorder, grossly disorganized behavior, and catatonic motor behavior. Positive symptoms may comprise two distinct dimensions: the "psychotic dimension” includes delusions and hallucinations and the "disorganization dimension” includes disorganized speech and behavior. Negative symptoms include, but are not limited to, affective flattening, alogia, and avolition. Affective flattening is generally displayed as restrictions in the range and intensity of emotional expression. Alogia is generally displayed as restrictions in the fluency and productivity of thought and speech. Avolition is generally displayed as restrictions in the initiation of goal-directed behavior.
  • Schizophrenia and other psychotic disorders include schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder and psychotic disorder not otherwise specified.
  • Schizoaffective disorder involves characteristic symptoms of schizophrenia and a major depressive, manic, or mixed depressive and manic episode.
  • Substance dependence and addiction can occur with a variety of substances, including but not limited to, alcohol, nicotine, cocaine, opioids, narcotics, hallucinogens, amphetamines, phencyclidines, phencyclidine-like substances, inhalants, and sedatives.
  • Substance-induced anxiety disorder can occur in response to substances which include, but not limited to, caffeine, cannabis, cocaine, hallucinogens, amphetamines, phencyclidines, phencyclidine-like substances, and inhalants.
  • Substance-induced mood disorder can occur in response to substances which include, but not limited to cocaine, hallucinogens, opioids, amphetamines, phencyclidines, phencyclidine-like substances, and inhalants.
  • Substance-related disorders can occur in response to one substance or to a combination of substances, such as in polysubstance-related disorder.
  • methods provided include the treatment of medication-induced psychiatric disorders or psychiatric disorders that result from treatment of a disease.
  • hedonistic homeostatic dysregulation is a neuropsychological behavioral disorder recognized in patients with Parkinson's disease undergoing dopamine replacement therapy. Dopamine replacement therapy in these patients appears to stimulate central dopaminergic pathways and lead to a behavioral disorder with some similarities to that associated with stimulant addiction. Giovannoni et al. (2000) /. Neurol. Neurosurg. Psychiatry 68:423-428.
  • Eating disorders can include anorexia nervosa, bulimia nervosa, and eating disorders not otherwise specified. These eating disorders may include binge eating.
  • methods provided are drawn to the treatment of the psychiatric illness associated with the eating disorder. In other embodiments, methods provided do not include the treatment of eating disorders. In certain embodiments, methods provided do not include the treatment of anorexia. In other embodiments, methods provided may be used for treating the psychiatric illness associated with anorexic patients. In certain embodiments, methods provided do not include the treatment of binge eating.
  • methods provided can be used to treat subjects experiencing intermittent excessive behaviors (IEB).
  • EEB characterize a variety of disorders including, binge eating, substance abuse, alcoholism, aberrant sexual conduct, and compulsive gambling. IEB occur when occasional normal behavioral excess is transformed into repetitive, intermittent, maladaptive behavioral excess. Corwin (2006) Appetite 46: 11-15.
  • methods provided can be used to treat subjects with personality disorders, including, but not limited to, schizoid personality disorder and schizotypal personality disorder.
  • Individuals with schizoid personality disorder may also experience symptoms of ,.. ⁇ , ,.. , f , , i ,, ; ... , .,, undertaken; ⁇ ;, n ,.,, o depreJi ⁇ J ⁇ abd/ortrMsilnt ' psyc ⁇ otfc episodes, particularly in response to stress.
  • Individuals with schizotypal personality disorder may also experience symptoms of anxiety, depression, and/or transient psychotic episodes.
  • methods provided may not include the treatment of somatoform disorders.
  • methods provided may include somatoform disorders but do not include the treatment of physical pain.
  • methods provided may include the treatment of the psychiatric illness associated with pain.
  • Cognitive impairment can often accompany psychiatric diseases and disorders.
  • cognitive impairments may be features of schizophrenia and bipolar disorder and cognitive deficits can adversely affect functional outcomes of these disorders.
  • Cognitive impairment associated with psychiatric disorders include, but are not limited to, problems in attention and/or vigilance, working memory, reasoning and/or problem solving, processing speed, visual learning, verbal learning and social cognition.
  • methods for treating cognitive impairment or deficits associated with psychiatric disorders in a subject comprising administering to a subject in need thereof an amylin or an amylin agonist, analog, or derivative in an amount effective to improve the cognitive impairment or deficit.
  • Methods for measuring cognitive impairment or deficits and for measuring improvements in cognitive function are well known in the art.
  • Amylin, amylin agonists, amylin analogs, or amylin derivatives may also be superior to some other antidepressant, anxiolytic, and/or antipsychotic agents, as it may improve symptoms of cognitive impairment accompanying the primary psychiatric disorder. This attribute of amylin may lead to greater compliance among patients being treated for psychiatric disease.
  • compounds that reduce or moderate stress, or regulate the stress pathway may be useful as pharmacotherapeutic agents.
  • compounds that can affect or regulate metabolic disturbances as well as psychiatric or behavioral processes would be useful as pharmacotherapeutic agents.
  • compounds that can attenuate or reverse metabolic disturbances would be useful as pharmacotherapeutic treatments of psychiatric diseases or disorders.
  • compounds useful in the methods provided may be amylin, amylin agonists, amylin analogs, and amylin derivatives.
  • amylin agonists may not include calcitonin and/or CGRP.
  • [0042jP C not only treat the psychiatric illness, but also alleviate the physical co-morbidities of the illness, would be expected to elicit an increased rate of treatment response and outcome success in patients with a psychiatric illness.
  • Physical co-morbidities like diabetes, exacerbate the morbidity that comes with psychiatric illness and lead to a reduction in treatment response.
  • Amylin and its agonists may be particularly useful in the methods described herein because of its anti-diabetic, anti-obesigenic, and appetite suppressant effects.
  • Amylin and its agonists may further be beneficial in aiding the subject with their ability to modify food preferences described in commonly-owned U.S. Pat. Application No. 60/666,681, filed on March 31, 2005, and PCT application attorney docket no. 0113-PCT-O, filed 31 March 2006, the contents of each are incorporated by reference in its entirety.
  • the methods do not include treatment of anorexia. In other embodiments, the methods include treating the psychiatric illness associated with anorexia.
  • Still another general aspect includes the use of the naturally occurring and peripherally secreted amylin peptide or an amylin agonist, analog, or derivative, for the treatment of psychiatric disorders.
  • methods for psychiatric disorders in a subject comprising administering to a subject in need thereof, an amylin or an amylin agonist, analog, or derivative in an amount effective to treat the psychiatric disorder.
  • the psychiatric disorders are of natural or unidentified etiology.
  • the psychiatric disorder may result from medication for or treatment of a different disease.
  • methods for treating medication-induced psychiatric disorders or psychiatric disorders that result from treatment of a disease in a subject comprising administering to a subject in need thereof an amylin or an amylin agonist, analog, or derivative in an amount effective to treat the psychiatric disorder.
  • an amylin or an amylin agonist, analog, or derivative in an amount effective to treat the psychiatric disorder.
  • the amylin peptide is a naturally secreted hormone, it may reduce the side effect profile commonly present in patients receiving the currently prescribed treatments and pharmaceuticals for psychiatric disorders.
  • Another general aspect includes the use of compounds that can treat both the psychiatric disease and metabolic disturbances present in a subject.
  • Amylin, amylin agonists, amylin analogs, or amylin derivatives may also be superior to some other antidepressant, anxiolytic, and/or antipsychotic agents, as it does not promote weight gain aiifilra ladtflaayMbde-iliiyiiliyil- This attribute of amylin may lead to greater compliance among patients being treated for psychiatric disease.
  • amylin or its agonists, analogs or derivatives may be used in conjunction with other psychiatric medications or therapies, such as those conventionally used to treat psychiatric disease, such as tricyclic antidepressants and the monamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), herbal antidepressants (e.g., St John's Wort or Hypericum), second generation antipsychotic medications (SGAs), psychoanalysis, cognitive-behavioral therapy, and interpersonal therapy.
  • psychiatric medications or therapies such as those conventionally used to treat psychiatric disease, such as tricyclic antidepressants and the monamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), herbal antidepressants (e.g.
  • amylin or amylin agonist When used in conjunction with other psychiatric medications or therapies, administration of the amylin or amylin agonist may occur concurrently or sequentially with the other psychiatric medications or therapies.
  • the amylin or amylin agonist may be administered during the same time period as the other psychiatric medication, during an overlapping time period as the other psychiatric medication, or in a time period that does not overlap with administration of the other psychiatric medication.
  • the beneficial qualities of an amylin or amylin agonist may counteract or moderate one or more of the unwanted side effects of currently available medications, e.g., weight gain, diabetes.
  • SGAs are effective therapeutics for the treatment of symptoms associated with schizophrenia and related psychotic conditions.
  • accumulating clinical data have revealed an association between the use of SGAs and weight gain, diabetes, and dyslipidemia (American Diabetes Association et al. (2004) Diabetes Care 27: 596-601).
  • Weight gain may be one contributing factor to a patient's non- compliance with his medication. So, as good as any medication may be, it does not provide any benefit to a patient that is not taking it, or not taking it properly.
  • Exemplary SGAs such as clozapine and olanzapine have been identified as being likely to produce weight gain; in addition, these two SGAs have also been associated with increased risk for both diabetes and dyslipidemia.
  • amylin and amylin agonists are also able to treat or aid in the treatment of diabetes and dyslipidemia.
  • the amylin agonist, pramlintide has been approved by the FDA as an adjunct therapy to insulin in the treatment of diabetes (type 1 and type 2). Accordingly, when used with other psychiatric medications, amylin and amylin agonists may not only provide an additional treatment to the psychiatric condition, but also be able to counteract at least a negative side effect of those other psychiatric medications.
  • a "subject” may include any mammal, including humans.
  • a “subject” may also include pets (e.g., dogs, cats, horses), as well as other animals.
  • Subjects may have at least one 1ISIHI)S- herein.
  • -Subjects who may benefit from the methods disclosed herein may be overweight or obese; however, they may also be lean. They may have a metabolic disorder or condition in addition to a psychiatric disorder. Exemplary metabolic disorders include diabetes, metabolic syndrome, insulin-resistance, and dyslipidemia. Subjects can be of any age.
  • these disorders can be found in young adults and adults (defined herein as those aged 65 or under) as well as infants, children, adolescents, and the elderly (defined herein as over the age of 65).
  • certain segments of the population may be particularly prone to having a particular condition, such as eating disorders in adolescents and young adults.
  • the elderly may be particularly susceptible to conditions such as depression.
  • treatment is an approach for obtaining beneficial or desired results, including clinical results.
  • Treating” or “palliating” a disease, disorder, or condition means that the extent, undesirable clinical manifestations of a condition, or both, of a disorder or a disease state are lessened and/or time course of the progression is slowed or lengthened, as compared to not treating the disorder.
  • beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of disorder, stabilized (i.e., not worsening) state of disorder, delay or slowing of disorder progression, amelioration or palliation of the disorder, and remission (whether partial or total), whether detectable or undetectable.
  • Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment. Further, treating does not necessarily occur by administration of one dose, but often occurs upon administration of a series of doses. Thus, a therapeutically effective amount, an amount sufficient to palliate, or an amount sufficient to treat a disease, disorder, or condition may be administered in one or more administrations.
  • amylin agonist can include one or more amylin agonists.
  • amylin may exert its psychiatric/behavioral effects by modulating GC-responsive sites (such as the brain) and impact functions that are normally modulated by GCs (e.g., CFR) expression and activity, behavior, autonomic nervous system activity, neuroendocrine function, and metabolism).
  • GCs e.g., CFR
  • amylin, its agonists, analogs, or derivatives may block or reduce the behavioral (e.g., anxiety, depression) and metabolic (e.g., feeding, obesigenic) effects of GCs, brain CRF, or chronic stress.
  • amylin may have some antidepressant, anxiolytic, and/or antipsychotic activities that are not directed related to it's anti-diabetic or anti-obesity activities.
  • __ __ any antidepressant, anxiolytic, and/or antipsychotic activities that are not directed related to it's anti-diabetic or anti-obesity activities.
  • __ __ any antidepressant, anxiolytic, and/or antipsychotic activities that are not directed related to it's anti-diabetic or anti-obesity activities.
  • Disruptions in the GC and CRF relationship can have profound effects on health.
  • chronic stress promotes palatable feeding (e.g., simple sugar, fat).
  • palatable food is available, as it abundantly is in modern societies, chronic stress increases the proportion of palatable calories consumed (Pecoraro et al. (2004) Endocrinology 145:3754-3762; Laugero (2004) Vitamins and Hormones, Volume 68. Ed. Gerald Litwack; Laugero et al. (2002) Endocrinology 143:4552-4562).
  • truncal obesity insulin resistance, hypertension, hypertriglyceridemia
  • truncal obesity is characterized by increased glucocorticoid activity, and it has been hypothesized that, through the activation of adrenocortical synthesis and secretion of GCs, chronic stress plays a significant role in the development of truncal obesity and the metabolic syndrome (Bjorntorp (2001) Obes. Rev.
  • Hyper- and hypo-cortisolemia are also well-documented features of psychiatric disease, and patients suffering from the metabolic syndrome show signs of abnormal Cortisol secretion and are more likely to present with a psychiatric disease such as major depression.
  • Chronic stress and the associated increase in central CRF activity are believed to play a critical role in the development of clinical depression, anxiety disorders, substance abuse, eating disorders, and metabolic syndrome (Chrousos et al. (2000) Int. J. Obes. Relat. Metab. Disord. 24:S50-S55; Koob (1999) Biol. Psychiatry 46:1167-1180).
  • small molecule CRF antagonists are currently being investigated for their therapeutic actions in patients with major depression, general anxiety disorder, eating disorders, and other stress related pathologies.
  • Amylin is a hormone that is co-secreted with insulin from the pancreatic ⁇ -cell and that has numerous metabolic effects, including glucoregulatory actions.
  • the glucoregulatory actions of amylin may be related to its effects on gastric emptying, suppression of inappropriately elevated postprandial glucagon secretion, and inhibition of food intake (Young (1997) Curr. Opin. in Endocrinology and Diabetes 4:282-290).
  • An amylin agonist analog, pramlintide is being developed for the treatment for type 1 and 2 diabetes (Baron et al. (2002) Curr. Drug Targets Immune Endocr. Metabol. Disord. 2:63-82) and has recently been approved by the FDA for such use.
  • amylin is also a good candidate for treating the metabolic syndrome. Moreover, amylin is a candidate for an anti-obesity drug for humans due to its effect on weight in animals (Mack et al. (2003) Diabetes 52 (Suppl. 1) A389).
  • Amylin agonists include amylin agonist analogs, examples of which are described in US Pat. 5,686,411; US Pat 6,610,824; US Pat 5,998,367; US Pat 6,087,334; US Provisional Application no. 60/617,468, filed 10/8/04; and PCT Application No. PCT/US2005/004631, all of which are incorporated herein by reference.
  • methods provided may not include the use of calcitonins.
  • the calcitonin is salmon calcitonin.
  • methods provided may not include the use of CGRP.
  • methods provided may not include the use of analogs of CGRP or calcitonin. Accordingly, it is contemplated that methods provided may include a proviso that excludes CGRP, calcitonin, or their analogs.
  • amylin is meant the human peptide hormone referred to as amylin and secreted from the beta cells of the pancreas, and species variations thereof, examples of which are described in U.S. Pat. No. 5,234,906, the contents of which are hereby incorporated by reference. More co-secreted with insulin by pancreatic beta cells in response to nutrient intake (see, e.g., Koda et al. (1992) Lancet 339:1179- 1180). In this sense, “amylin,” “wild-type amylin,” and “native amylin,” i.e., unmodified amylin, are used interchangeably. Amylin is also sometimes referred to as "IAPP.”
  • agonist is meant a compound which elicits a biological activity of amylin, for example, having a potency better than amylin, or within five orders of magnitude (plus or minus) of potency compared to amylin, for example 4, 3, 2, or 1 order of magnitude, when evaluated by art- known measures such as, for example, receptor binding/competition studies as described herein.
  • the term agonist refers to a compound which elicits a biological effect similar to that of native amylin, for example a compound (1) having activity in a food intake, gastric emptying, pancreatic secretion, or weight loss assay (PCT Application No. PCT/US2005/004631, filed on Feb. 11, 2005, and incorporated by reference) similar to the native human reference peptide, and/or (2) which binds specifically in a reference receptor assay or in a competitive binding assay with amylin.
  • the agonists will bind in such assays with an affinity of better than 1 ⁇ M, and, in another embodiment, with an affinity of better than 1-5 nM.
  • Such agonists may comprise a polypeptide comprising an active fragment of amylin or a small chemical molecule.
  • an agonist is a peptide, not a small chemical molecule. It is, however, contemplated that in certain embodiments, salmon calcitonin, calcitonin, CGRP, and/or their respective analogs may be excluded from the scope of amylin agonist with proviso language.
  • an amylin agonist is not a small chemical molecule and small chemical molecules may be excluded from the scope of amylin agonist with proviso language.
  • Agonists include amylin analogs and amylin derivatives.
  • analog is meant a peptide whose sequence is derived from that of amylin including insertions, substitutions, extensions, and/or deletions, having at least some amino acid identity to amylin or region of an amylin peptide.
  • Analogs may have at least 50 or 55% amino acid sequence identity with a native amylin, or at least 70%, 80%, 90%, or 95% amino acid sequence identity with a native amylin.
  • such analogs may comprise conservative or non-conservative amino acid substitutions (including non-natural amino acids and L and D forms).
  • Amylin agonist analogs are analogs as herein described and function as an amylin agonist.
  • a “derivative” is defined as a molecule having the amino acid sequence of a native amylin or analog, but additionally having a chemical modification of one or more of its amino acid side groups, ⁇ -carbon atoms, terminal amino group, or terminal carboxylic acid group.
  • a chemical modification includes, but is not limited to, adding chemical moieties, creating new bonds, and aeid side groups include, without limitation, acylation of lysine ⁇ -amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine.
  • Modifications of the terminal amino include, without limitation, the desamino, N-lower alkyl, N-di- lower alkyl, constrained alkyls (e.g. branched, cyclic, fused, adamantyl) andN-acyl modifications.
  • Modifications of the terminal carboxy group include, without limitation, the amide, lower alkyl amide, constrained alkyls (e.g. branched, cyclic, fused, adamantyl) alkyl, dialkyl amide, and lower alkyl ester modifications.
  • Lower alkyl is C1-C4 alkyl.
  • one or more side groups, or terminal groups may be protected by protective groups known to the ordinarily-skilled synthetic chemist.
  • the ⁇ -carbon of an amino acid may be mono- or dimethylated.
  • Human amylin (hAmylin or h-amylin) has the following amino acid sequence: Lys- Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe- Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr (SEQ ED NO:1).
  • Rat amylin (rAmylin) has the following sequence: KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY (SEQ DD NO:2). The use of amylins from any species is contemplated.
  • Amylin agonists contemplated in the use in the methods disclosed herein include those described in U.S. Patent Nos. 5,686,411, 6,114,304, and 6,410,511, and PCT Application Publication No. WO 93/10146, the contents of which are herein incorporated by reference in their entirety.
  • Such compounds include those having formula I: GIy- 25 I 1 -J 1 -LeU-KrL 1 - 30 ThT-Mi-VaI-GIy-SeT- 35 ASn-ThT-TyT (SEQ DD NO:3) wherein A 1 is Lys, Ala, Ser or hydrogen;
  • B 1 is Ala, Ser or Thr
  • Ci is VaI, Leu or De
  • D 1 is His or Arg
  • Ei is Ser or Thr
  • Fi is Ser, Thr, GIn or Asn
  • G 1 is Asn, GIn or His
  • H 1 is Phe, Leu or Tyr
  • Ii is Ala or Pro
  • J 1 is De, VaI, Ala or Leu;
  • Ki is Ser, Pro, Leu, He or Thr;
  • L 1 is Ser, Pro or Thr
  • M 1 is Asn, Asp, or GIn; P" I! “ : ⁇ ' a ra £nIJsEyg ⁇ id ⁇ pinieil ⁇ f Sected amino acid residues having side chains which are chemically bonded to each other to form an intramolecular linkage.
  • the C-terminal portion can be amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy, aralkyloxy or carboxyl.
  • Suitable side chains for X and Y include groups derived from alkyl sulfhydryls which may form disulfide bonds; alkyl acids and alkyl amines which may form cyclic lactams; alkyl aldehydes or alkyl halides and alkylamines which may condense and be reduced to form an alkyl amine bridge; or side chains which may be connected to form an alkyl, alkenyl, alkynyl, ether or thioether bond.
  • Preferred alkyl chains include lower alkyl groups having from about 1 to about 6 carbon atoms.
  • compositions and methods of use provided herein are directed to agonist analogues of SEQ ID NO:3 which are not bridged, and wherein X and Y are independently selected from Ala, Ser, Cys, VaI, Leu and lie or alkyl, aryl, or aralkyl esters and ethers of Ser or Cys.
  • Exemplary compounds include, but are not limited to des ⁇ Lys-h-amylin (SEQ ID NO:4), 28 Pro-h-amylin (SEQ ID NO:5), 25 ' 28 ' 29 Pro-h-amylin (SEQ ID NO:6), 18 Arg 25 ' 28 Pro-h-amylin (SEQ ID NO:7), and des- 1 Lys 18 Arg 25 ' 28 Pro-h-amylin (SEQ ID NO: 8), which all show amylin activity in vivo in treated test animals, (e.g., provoking marked hyperlactemia followed by hyperglycemia).
  • certain of the compounds provided herein have also been found to possess more desirable solubility and stability characteristics when compared to human amylin.
  • examples of these compounds include 25 Pro 26 Val 28 ' 29 Pro-h-amylin (SEQ ID NO:9), 25 ' 28>29 Pro-h-amylin, and 18 Arg 25 ' 28 Pro-h-amylin.
  • Other compounds include 18 Arg 25l28>29 Pro-h-arnylin (SEQ ID NO: 10), des- 1 Lys 18 Arg 25 ' 28 ' 29 Pro-h-amylin (SEQ ID NO:11), des- 1 Lys 25 ' 28>29 Pro-h-amylin (SEQ ID NO:12), 25 Pro 26 Val 28 ' 29 Pro-h-amylin (SEQ ID NO: 13), 23 Leu 25 Pro 26 Val 28>29 Pro-h-amylin (SEQ ID NO: 14), 23 Leu 25 Pro 26 Val 28 Pro-h-amylin (SEQ ID NO: 15), des- 1 Lys 23 Leu 25 Pro 26 Val 28 Pro-h-amylin (SEQ ID NO: 16), 18 Arg 23 Leu 25 Pro 26 Val 28 Pro-h-amylin (SEQ ID NO: 17), 18 Arg 23 Leu 25l28 ' 29 Pro-h-amylin (SEQ ID NO: 18), 18 Arg 23 Leu 25
  • Amylin agonists contemplated in the use in the methods disclosed herein include Amylin Family Polypeptide-6 (AFP-6) analogs as described in US Provisional Application No. 60/617,468 and PCT Application No. PCT/US05/036456, which are herein incorporated by reference in their entirety.
  • AFP-6 Amylin Family Polypeptide-6
  • a mature AFP-6 peptide, also known as intermedin, has the following amino acid sequence
  • AFP-6 or AFP-6 analogs may or may not be amidated at the C-terminal end.
  • AFP-6 analogs include those having formula II: X 1 -X 2 -X 3 -X 4 -X 5 -Xe-X 7 -Xs-QVQNLSHRLWQL-X 21 -X 22 - X 23 -X 24 -X 25 -Xi 6 -Xa?- X 2 S-SAPV-X 33 -PSSPHSY (SEQ ID NO:33) wherein
  • Xi is absent, TQAQLLRVG (SEQ ID NO:34), any of one or more consecutive amino acids of SEQ ID NO:34, N-aryl, or N-acyl with a substituent selected from a C1-C18 alkyl, a substituted alkyl or a heteroaryl moiety;
  • X 2 is M, S, C, substituted L, K, D, or E, where the side chain can be linked via an amide bond, or any amino acid that can form a bond with Xg, for example a disulfide or an amide bond;
  • X 3 is V, D, L, G, N, A, or S;
  • X 4 is V, D, L, G, N, A, S or T;
  • X 5 is V, D, L, G, N, A, or S;
  • X 6 is V, D, L, G, N, A, S, or absent;
  • X 7 is T, S, Hse (homoSER), Ahb ((S)-2-Amino-3-hydroxy-3-methybutanoic acid) or (Ahp) (2R,3R)-2-Amino-3-hydroxy-4-methylpentanoic acid;
  • X 8 is M, S, C, substituted L, K, D, or E, or any amino acid that can form a bond with X 2 , for example a disulfide or an amide bond;
  • X 21 is M, G, P, A, or absent
  • X 22 is M, G, P, A, or absent
  • X 23 is M, G, P, A, or absent
  • X 24 is M, G, P, A, or absent
  • X 25 is M, G, P, A, or absent
  • X 26 is R or absent, wherein when X 26 is absent, X 27 is absent;
  • X 27 is Q or absent, wherein when X 27 is absent, X 26 is absent;
  • X 28 is D or E
  • X 33 is D or E; and biologically active fragments thereof.
  • X 1 is Q or absent
  • X 2 is V or absent
  • X 13 is M, G, P, A, or absent
  • X 14 is M, G, P, A, or absent
  • X 15 is M, G, P, A, or absent
  • X 16 is M, G, P, A, or absent
  • X 17 is M, G, P, A, or absent
  • X 18 is R or absent, wherein when X 18 is absent, X 19 is absent;
  • X 19 is Q or absent, wherein when X 19 is absent, X 18 is absent
  • X 25 is D or E; and biologically active fragments thereof.
  • Amino acid sequences of exemplary AFP-6 analogs for use in the disclosed methods include:
  • RVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO:36) GCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO:37) CVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO:38) QVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO:39) VQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO:40) VQNLSHRL-QLMGPAGRQDSAPVDPSSPHSY (SEQ ID NO:41) TQAQLLRVGCVLGTCQVQNLSHRLWQLRQDSAPVDPSSPHSY (SEQ ID NO:42) TQAQLLRVGCVLGTCQVQNLSHRLWQLDSAPVDPSSPHSY (SEQ ID NO:43) VGCVLGTCQV
  • Amylin agonists contemplated in the use in the methods disclosed herein include analogs identified in US Patent No. 6,087,334, the contents of which is hereby incorporated by reference.
  • Such useful amylin agonists include analogs of formula IV: X 1 -Xaa 1 -X 2 -Xaa 2 -X 3 -Xaa 3 - X 4 -Xaa 4 -X 5 -Xaa 5 -X 6 (SEQ ID NO:67) wherein
  • X 1 is Lys, Arg or absent
  • X 2 is Xaa 6 Xaa 7 Xaa 8 Xaa 9 (SEQ. ID. NO.68) or Z-Xaa 10 SerThr, provided that if X 2 is Z- XaaioSerThr, then X 1 and Xaa t are both absent;
  • X 3 is AlaThr, AlaSer, SerMet, GluThr or ValThr;
  • X 4 is ArgLeuAla, HisLeuAla, ArglleAla, Lys ⁇ eAla, ArgMetAla, HisMetAla, LysMetAla or ArgLeuThr;
  • X 5 is PheLeu, Phelle, PheMet, TyrLeu, Tyrlle, TyrMet, Trplle or TrpMet;
  • X 6 is ArgSerSerGlyTyr (SEQ ID NO:69), LysSerSerGlyTyr (SEQ ID NO:70), HisSerSerGlyTyr (SEQ ID NO:71), ProSerSerGlyTyr (SEQ ID NO:72), ArgSerArgGlyTyr (SEQ ID NO:73), ArgThrSerGlyTyr (SEQ ID NO:74), ArgAlaSerGlyTyr (SEQ ID NO:75), AlaSerSerGlyTyr (SEQ ID NO:76), ArgSerAlaGlyTyr (SEQ ID NO:77), HisSerAlaGlyTyr (SEQ ID NO:78), ArgSerGlyTyr (SEQ ID NO:79), ArgSer, LysSer, HisSer, ArgThr, ProSer or Arg;
  • Xaa ⁇ is Cys or absent
  • Xaa 2 is Cys or Ala
  • Xaa 3 is GIn, Ala or Asn
  • X.&& 4 is Asn, Ala or GIn; P C%4 y %Pfiaf S]IWLIU, PentylGly, or t-butylGly; Xaa 7 is Thr, Ser, Met, VaI, Leu or lie; Xaa 8 is Ala or VaI; Xaa 9 is Thr or Ser; Xaa 10 is Leu, VaI, Met or lie;
  • Z is an alkanoyl group of about 1 to about 8 carbon atoms or absent; and pharmaceutically acceptable salts thereof.
  • each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.
  • Amylin agonists contemplated in the use in the methods disclosed herein include the amylin family peptides and analogs described in PCT Application No. PCIYUS 2005/004631, which is herein incorporated by reference in its entirety.
  • Such useful amylin agonists may include analogs comprising an amino acid sequence of formula V: Xaaji X Xaa 3 Xaa4 Xaa 5 Xaa 6 Y Xaag Xaa 9 Xaa ⁇ Xaa ⁇ Xaa 12 Xaa ⁇ Xaa 14 Xaa 15 Xaa 16 Xaa 17 Xaa 18 Xaa 19 Xaa 2 o Xaa 21 Xaa 22 Xaa 23 Xaa 24 Xaa 25 Xaa 26 Xaa 27 Xaa 28 Xaa 29 Xaa 30 Xaa 31 Xaa 32 (SEQ DD NO: 80) wherein
  • Xaa ! is A, C, hC (homoCys), D, E, F, I, L, K, MC (homoLys), R, hR (homoArg), S, Hse(homoSer), T, G, Q, N, M, Y, W, P, Hyp (hydroxyPro), H, V or absent;
  • Xaa 3 is A, D, E, N, Q, G, V, R, K, hK, hR, H, I, L, M, or absent;
  • Xa& t is A, I, L, S, Hse, T, V, M, or absent;
  • Xaa 5 is A, S, T, Hse, Y, V, I, L, or M;
  • Xaa ⁇ s is T, A, S, Hse, Y, V, I, L, or M;
  • Xaa 8 is A, V, I, L, F, or M;
  • Xaa 9 is L, T, S, Hse, V, I, or M;
  • Xaa 10 is G, H, Q, K, R, N, hK, or hR;
  • Xaa ⁇ is K, R, Q, N, hK, hR, or H;
  • Xaa 12 is L, I, V, F, M, W, or Y;
  • Xaaj 3 is A, F, Y, N, Q, S, Hse, orT;
  • Xaau is A, D, E, G, N, K, Q, R, H, hR, or hK;
  • Xaa 15 is A, D, E, F, L, S, Y, I, V, or M;
  • Xaa 15 is L, F, M, V, Y, or I; p !i::;:ik; ⁇ yii ⁇ r ⁇ iN; msit 1 Si v ;
  • Xaa 18 is K, hK, R, hR, H, u (Cit), or n (Orn);
  • Xaa 19 is F, L, S, Hse,V, I, T, or absent;
  • Xaa 20 is H, R, K, hR, hK, N, Q, or absent;
  • Xaa 2 i is T, S, Hse, V, I, L, Q, N, or absent;
  • Xaa 22 is F, L, M, V, Y, or I;
  • Xaa 23 is P or Hyp
  • Xaa 24 is P, Hyp, R,K, hR, hK, or H;
  • Xaa 25 is T, S, Hse, V, I, L, F, or Y;
  • Xaa 26 is N,Q, D, or E;
  • Xaa 27 is T, V, S, F, I, or L;
  • Xaa 28 is G or A
  • Xaa 29 is S, Hse, T, V, I, L, or Y;
  • Xaa 30 is E, G, K, N, D, R, hR, hK, H, or Q;
  • Xaa 31 is A, T, S, Hse, V, I, L, F, or Y;
  • Xaa 32 is F, P, Y, Hse, S, T, or Hyp; wherein X and Y are capable of creating a bond and are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage such as disulfide bonds; amide bond; alkyl acids and alkyl amines which may form cyclic lactams; alkyl aldehydes or alkyl halides and alkylamines which may condensed and be reduced to form an alkyl amine or imine bridge; or side chains which may be connected to form an alkyl, alkenyl, alkynyl, ether or thioether bond.
  • Alkyl chains may include lower alkyl groups having from about 1 to about 6 carbon atoms.
  • the intramolecular linkage may be a disulfide, amide, imine, amine, alkyl or alkene bond.
  • X and Y are independently selected from Ser, Asp, GIu, Lys, Orn, or Cys.
  • X and Y are Cys and Cys.
  • X and Y are Ser and Ser.
  • X and Y are Asp and Lys or Lys and Asp.
  • Useful amylin agonists may also include analogs comprising the amino acid sequence of formula VI: Xaai Xaa 2 Xaa 3 Xaa 4 Xaa 5 Xaa 6 Xaa 7 Xaa 8 Xaa 9 Xaa 10 Xaa ⁇ Xaa 12 Xaa 13 Xaa 14 Xaa ⁇ Xaa 16 Xaa 17 Xaa 18 Xaa 19 Xaa 2 o Xaa 21 Xaa 22 P Xaa 24 T N Xaa 2 ⁇ G S Xaa 30 Xaa 31 Xaa 32 (SEQ ID NO:81) wherein
  • Xaai is A, C, D, F, I, K, S, T, or absent;
  • Xaa 2 is C, D, S, or absent
  • Xaa 3 is A, D, N, or absent;
  • Xaa 5 is A or S
  • Xaa 6 is T, A, S, or V;
  • Xaa 7 is C, K, or A
  • Xaa 8 is A, V, L, orM
  • Xaa 9 is L or T
  • Xaa 10 is G, H, or Q;
  • Xaa ⁇ is K, R, Q, or hArg
  • Xaa 12 is L, W, or Y;
  • Xaa 13 is A, F, N, Q, S, or T;
  • Xaa J4 is A, D, E, G, N, K, Q, or R;
  • Xaa 15 is A, D, E, F, L, S, or Y;
  • Xaa 16 is L, or F
  • Xaa 17 is H, Q, S, or V;
  • Xaa 18 is K, R, hArg, u (Cit), or n (Orn);
  • Xaa 19 is F, L, S, or absent
  • Xaa 20 is H, Q, or absent
  • Xaa 21 is T, N, or absent
  • Xaa 22 is F, L, M, V, or Y;
  • Xaa 24 is P or R
  • Xaa 27 is T or V
  • Xaa 30 is E, G, K, or N;
  • Xaa 31 is A or T
  • Xaa 32 is F, P, or Y.
  • Useful amylin agonists may also include analogs comprising the amino acid sequence of formula VII: Xaai Xaa 2 Xaa 3 XBa 4 Xaa 5 T Xaa 7 Xaa 8 Xaa 9 Xaa 10 Xaa ⁇ L Xaa 13 Xaa 14 Xaa 15 L Xaa 17 Xaa 18 Xaa 19 Xaa 20 Xaa 21 Xaa 22 P Xaa 24 T N Xaa 27 G S Xaa 30 Xaa 31 Xaa 32 , (SEQ ID NO:82) wherein
  • Xaai is A, C, F, I, K, S, or absent;
  • Xaa 2 is C, D, or S;
  • Xaa 3 is A, D or N;
  • XaB 4 is A, L or T;
  • Xaas is A or S
  • Xaa 7 is C or K; Xaa 9 is L or T;
  • Xaa ⁇ o is G, H, or Q;
  • Xaa ⁇ is K, R, or hArg
  • Xaa 13 is A, F, N, S, or T;
  • Xaa l4 is A, D, E, G, N, Q, or R;
  • Xaa 15 is A, E, F, L, S, or Y;
  • Xaa 17 is H, S, or V;
  • Xaa 18 is K, R, hArg, u (Cit), or n (Orn);
  • Xaa 19 is F, L, or S;
  • Xaa 2 o is H or Q
  • Xaa 21 is T or N
  • Xaa 22 is F, L, M, V, or Y;
  • Xaa 24 is P or R
  • Xaa 27 is T, or V;
  • Xaa 30 is E, G, K, or N;
  • Xaa 31 is A, or T;
  • Xaa 32 is F, P, or Y.
  • Useful amylin agonists may also include analogs comprising the amino acid sequence of formula VIII: Xaa ! Xaa 2 Xaa 3 Xaa 4 Xaa 5 Xaa 6 Xaa 7 Xaa 8 Xaa 9 Xaaio Xaa ⁇ Xaa 12 Xaa 13 Xaa 14 Xaa 15 Xaai 6 Xaa 17 Xaa 18 Xaa 19 Xaa 2 o Xaa 21 Xaa 22 P Xaa 24 T N Xaa 27 G S Xaa 30 Xaa 31 Xaa 32 (SEQ ID NO: 83) wherein
  • Xaa ! is A, C, D, F, K, T, or absent;
  • Xaa 2 is A, C, D, S, or absent;
  • Xaa 3 is A, D, N, or absent
  • Xa ⁇ is A, L, T, or absent
  • Xaa 5 is A or S
  • Xaa 6 is A, S, T, or V;
  • Xaa 7 is A, C, or K
  • Xaa 8 is A, L, M, or V;
  • Xaa 9 is L or T
  • Xaa 10 is G, H, or Q;
  • Xaa ⁇ is K, Q, or R;
  • Xaa 12 is L, W, or Y;
  • Xaa 14 is A, D, E, G, K, N, Q, or R;
  • Xaai 5 is A, D, E, F, L, S, or Y;
  • Xaa 16 is F or L
  • Xaa 17 is H, Q, S or V;
  • Xaa 18 is K, or R;
  • Xaa 19 is F, L, S, or absent
  • Xaa 20 is H, K, Q, or absent
  • Xaa 21 is Q, T, or absent
  • Xaa 22 is F, L, or Y;
  • Xaa 24 is P or R
  • Xaa 27 is T or V
  • Xaa 30 is E, K or N;
  • Xaa 31 is A or T
  • Xaa 32 is F,Y, or absent.
  • the sequence of formula V, VI, VII, or VIII further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more modifications of substitutions, insertions, deletions, elongations and/or derivatizations.
  • the sequence of formula V, VI, VII, or VTH comprises a deletion at position 24.
  • the sequence of formula V, VI, or VH comprises a VaI inserted between amino acids at positions 22 and 23.
  • the sequence of formula V, VI, or VDL comprises a GIn inserted between positions 22 and 23.
  • the sequence of formula V, VI, or VII comprises a sequence of Gln-Thr-Tyr between positions 22 and 23.
  • the sequence of formula V, VI, or VH comprises a sequence of Leu-Gln-Thr-Tyr (SEQ ID NO: 84) between positions 22 and 23.
  • the modifications of formula V, VI, or VQ may be at the N-terminal end.
  • the N-terminal portion of formula V, VI, or VII has an added octylglycine.
  • the N-terminal portion of formula V, VI, or VII has an added isocap.
  • Other embodiments are described in PCT Application No. PCT/US2005/004631 and incorporated by reference.
  • compositions and methods provided herein can be in the acid or amide form.
  • compositions and methods provided herein include:
  • KCNTATCVLGKLSQELHRLQTYPRTNTGSNTY (SEQ ID NO: 156) KCNTATCVLGRLSQELHRLQTLPRTNTGSNTY (SEQ ID NO: 157) KCNTATCVLGRLSQELHRLQTYPPTNTGSNTY (SEQ ID NO: 158) KCNTATCVLGRLSQELHRLQTYPRTNVGSNTY (SEQ ID NO: 159) KCNTATCVLGRLSQELHRLQTLPPTNVGSNTY (SEQ ID NO: 160) KCNTATCVLGRLANFLHRLQTYPRTNTGSNTY (SEQ ID NO: 161) ACNTATCVLGRLSQELHRLQTYPRTNTGSNTY (SEQ ID NO: 162) KCNAATCVLGRLSQELHRLQTYPRTNTGSNTY (SEQ ID NO: 163) KCNTAACVLGRLSQELHRLQTYPRTNTGSNTY (SEQ ID NO: 164) CANLSTCVLGRLSQELHRLQ
  • compounds comprising the amino acid sequence KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY (SEQ ID NO:253) are of particular use in the disclosed methods.
  • lpt C ii ⁇ Mi ⁇ eU'clf't ⁇ ie' ⁇ ySn ⁇ if ⁇ 'a ⁇ i'd analogs are also included within the methods provided in which the stereochemistry of individual amino acids may be inverted from (L)/S to (D)/R at one or more specific sites.
  • the agonists and analogs modified by glycosylation of Asn, Ser and/or Thr residues are also be biologically active fragments of the peptides (native, agonist, analog, and derivative) herein described.
  • Agonist and analogs of amylin that contain less peptide character are included within the methods provided.
  • salts for use in the methods form salts with various inorganic and organic acids and bases.
  • Such salts include salts prepared with organic and inorganic acids, for example, HCl, HBr, H 2 SO 4 , H 3 PO 4 , trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid.
  • Salts prepared with bases include, for example, ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkali earth salts (such as calcium and magnesium salts).
  • the compounds form acetate, hydrochloride, and trifluoroacetate salts.
  • Amylin agonists useful in the compositions and methods provided herein may also include fragments of amylin and its analogs as described above as well as those described in EP 289287, the contents of which are herein incorporated by reference.
  • Amylin agonists analogs may also be compounds having at least 60, 65, 70, 75, 80, 85, 90, 95, or 99% amino acid sequence identity to SEQ ID NO:1, or any of the amylin analogs specifically described herein having amylin activity.
  • Amylin agonists also include small chemical molecules and non-peptide molecules, for example those based on small molecule chemistry. In some embodiments, amylin agonists are not small chemical molecules.
  • Amylin activity may include at least one of the activities known in the art as described below. Amylin activity may also include the ability of amylin to modulate the stress response, affect GC and/or affect CFR activity in a body. Desirable amylin agonists or amylin analogs may have at least one property shared by the antipsychotic, antidepressant, and anxiolytic agents used herein in Examples 2 and 3. Amylin agonist analogs also include insertions, deletions, extensions, truncations, and/or substitutions in at least one or more amino acid positions of SEQ ID NO: 1 or any of the amylin analogs specifically described herein.
  • the number of amino , _ , , acid ini : efio ' ns ⁇ ' ciyeio ⁇ Ji ;; y ' siyiMt ⁇ l)ni may be at least 5, 10, 15, 20, or 25 amino acid insertions, deletions, or substitutions.
  • the number of amino acid insertions, deletions, or substitutions may be not more than 5, 10, 15, 20, 25, or 30 amino acid insertions, deletions, or substitutions. Insertions, extensions, or substitutions may be with other natural amino acids, synthetic amino acids, peptidomimetics, or other chemical compounds.
  • amylin agonists may not include calcitonins and/or CGRPs.
  • calcitonins and/or CGRPs may be excluded from the scope of amylin agonist in the treatment of mood disorders, anxiety disorders or substance-related disorders.
  • calcitonins and/or CGRPs may be included in the scope of amylin agonists for other conditions like sleeping or eating disorders.
  • amylin agonists, useful in methods provided may not include calcitonin and/or CGRP analogs.
  • amylin agonists or amylin agonist analogs are recognized as referring to compounds which, by directly or indirectly interacting or binding with one or more receptors, mimics an action of amylin. They may also be referred to as amylinomimetics.
  • Activity as amylin agonists and/or analogs can be confirmed and quantified by performing various screening assays, including the nucleus accumbens receptor binding assay, the soleus muscle assay, a gastric emptying assay, or by the ability to induce hypocalcemia or reduce postprandial hyperglycemia in mammals.
  • Screen assays including the nucleus accumbens receptor binding assay, the soleus muscle assay, a gastric emptying assay, or by the ability to induce hypocalcemia or reduce postprandial hyperglycemia in mammals.
  • Methods of testing compounds for amylin activity are known in the art. Exemplary screening methods and assays for testing amylin agonists are described in U.S. Patent Nos. 5,264,372 and 5,686,411, which are incorporated herein by reference.
  • the receptor binding assay a competition assay that measures the ability of compounds to bind specifically to membrane-bound amylin receptors.
  • a preferred source of the membrane preparations used in the assay is the basal forebrain which comprises membranes from the nucleus accumbens and surrounding regions. Compounds being assayed compete for binding to these receptor preparations with 125 I Bolton Hunter rat amylin. Competition curves, wherein the amount bound (B) is plotted as a function of the log of the concentration of ligand, are analyzed by computer using analyses by nonlinear regression to a 4-parameter logistic equation (INPLOT program, GraphPAD Software, San Diego, CA) or the ALLFIT program of DeLean et al. (ALLFIT, Version 2.7 (NIH, Bethesda, Md. 20892)). Munson et al. (1980) Anal. Biochem. 107:220-239.
  • Assays of biological activity of amylin agonists/analogs in the soleus muscle may be performed using previously described methods (Leighton et al. (1988) Nature 335:632-635; Cooper et al. (1988) Proc. Natl. Acad. ScL USA 85:7763-7766), in which amylin agonist activity may be assessed by measuring the inhibition of insulin-stimulated glycogen synthesis.
  • an exemplary method includes soleus muscle strips prepared from 12-h fasted male Wistar rats. Theêt . tendonl J o ⁇ '1 ⁇ e- i niycM l 'yre > ligatla DbfordWachment to stainless steel clips.
  • Muscle strips are pre- incubated in Erlenmeyer flasks containing 3.5 ml Krebs-Ringer bicarbonate buffer, 7mM N-2- hydroxyethyl-peperazine-N'-2-ethane-sulphonic acid, pH 7.4, and 5.5 mM pyruvate. Flasks are sealed and gassed continuously with O 2 and CO 2 in the ratio 19:1 (v/v). After pre-incubation of muscles in this medium for 30 min at 37°C in an oscillating water bath, the muscles strips are transferred to similar vials containing identical medium (except pyruvate) with added [U- 14 C] glucose (0.5 ⁇ Ci/ml) and insulin (100 ⁇ U/ml).
  • the flasks are sealed and re-gassed for an initial 15 min in a 1-h incubation. At the end of the incubation period, muscles are blotted and rapidly frozen in liquid N 2 .
  • the concentration of lactate in the incubation medium can be determined spectrophotometrically and [U- 14 C] glucose incorporation in glycogen measured.
  • tritiated glucose In a tritiated glucose method, conscious rats are gavaged with tritiated glucose in water. The rats are gently restrained by the tail, the tip of which is anesthetized using lidocaine. Tritium in the plasma separated from tail blood is collected at various timepoints and detected in a beta counter. Test compounds are normally administered about one minute before gavage.
  • Amylin agonist compounds may exhibit activity in the receptor binding assay on the order of less than about 1 to 5 nM, in some embodiments less than about 1 nM and in some embodiments less than about 50 pM.
  • amylin agonist compounds may show EC 5 o values on the order of less than about 1 to 10 micromolar.
  • amylin agonist compounds show ED 50 values on the order of less than 100 ⁇ g/rat.
  • compounds provided herein may be prepared using standard solid-phase peptide synthesis techniques, for example using an automated or semiautomated peptide synthesizer.
  • an ⁇ -N- carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N- methylpyrrolidinone or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine.
  • the ⁇ -N-carbamoyl protecting group is removed from the resulting peptidl-rSsi ⁇ f l ⁇ sing'-iai 1 re!yj
  • Suitable N- protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl (Fmoc) being preferred herein.
  • tBoc t-butyloxycarbonyl
  • Fmoc fluorenylmethoxycarbonyl
  • amylin, amylin agonists, amylin analogs, and amylin derivatives may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses.
  • pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang et al. (1988) Journal of Parenteral Science and Technology Technical Report No. 10, Supp. 42:2S.
  • the compounds may be formulated into a stable, safe pharmaceutical composition for administration to a patient.
  • Pharmaceutical formulations contemplated for use in the methods described herein may comprise approximately 0.01 to 6.0% (w/v), or 0.05 to 1.0%, of the compound; approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer allowing a pH of the final composition of from about 3.0 to about 7.0; approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl-, ethyl-, propyl- and butyl- parabens and phenol. Such a preservative is generally included if the formulated peptide is to be included in a multiple use product.
  • a pharmaceutical formulation may contain a range of concentrations of the compound, e.g., between about 0.01% to about 98% (w/v), or between about 1 to about 98% (w/v), or between 80% and 90% (w/v), or between about 0.01% to about 50% (w/v), or between about 10% to about 25% (w/v) in this embodiment.
  • a sufficient amount of water for injection may be used to obtain the desired concentration of solution.
  • Additional tonicifying agents such as sodium chloride, as well as other known excipients, may also be present, if desired. In some cases, such excipients are useful in maintenance of the overall tonicity of the formulation.
  • An excipient may be included in the presently described formulations at various concentrations. For example, an excipient may be included in the concenfM ⁇ oIVyiJi ⁇ ' Mol 20% (w/w), about 0.02% and 0.5% (w/w), about 0.02% to about 10% (w/w), or about 1 % to about 20% (w/w). In addition, similar to the present formulations themselves, an excipient may be included in solid (including powdered), liquid, semisolid or gel form.
  • liquid vehicles are suitable for use in the present peptide formulations, for example, water or an aqueous/organic solvent mixture or suspension.
  • the pharmaceutical formulations may be composed in various forms, e.g., solid, semisolid or liquid.
  • solid as used herein, is meant to encompass all normal uses of this term including, for example, powders and lyophilized formulations.
  • the presently described formulations may be lyophilized.
  • buffer when used with reference to hydrogen-ion concentration or pH, refer to the ability of a system, particularly an aqueous solution, to resist a change of pH on adding acid or alkali, or on dilution with a solvent.
  • An example of the former system is acetic acid and sodium acetate.
  • the change of pH is slight as long as the amount of hydronium or hydroxyl ion added does not exceed the capacity of the buffer system to neutralize it.
  • the stability of a peptide formulation is enhanced by maintaining the pH of the formulation in the range of about 3.0 to about 7.0 when in liquid form.
  • the pH of the formulation is maintained in the range of about 3.5 to 5.0, or about 3.5 to 6.5, or about 3.7 to 4.3, or about 3.8 to 4.2.
  • a particular pH may be about 4.0. While not seeking to be bound by this theory, it is presently understood that, in some embodiments, where the pH of the pharmaceutical formulation exceeds 5.5, chemical degradation of the peptide may be accelerated such that the shelf life is less than about two years.
  • the buffer used in the practice of the present methods is an acetate buffer (typically at a final formulation concentration of from about 1-5 niM, e.g., 1.5 mM, to about 60 mM), phosphate buffer (typically at a final formulation concentration of from about 1-5 mM, e.g., 1.5 mM, to about 30 mM) or glutamate buffer (typically at a final formulation concentration of from about 1-5 mM, e.g., 1.5 mM, to about 60 mM).
  • the buffer is acetate at a final formulation concentration of from about 5 mM to about 30 mM.
  • a stabilizer may be included in the present formulation but, and importantly, is not necessarily needed. If included, however, a stabilizer useful in the practice of the present foimuliffiti Is 4balebfe ' yitafe-i ⁇ 'i' polyhfdric alcohol: A suitable stabilizer useful in the practice of the present methods is approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol.
  • the polyhydric alcohols and carbohydrates share the same feature in their backbones, i.e., -CHOH- CHOH-, which is responsible for stabilizing the proteins.
  • the polyhydric alcohols include such compounds as sorbitol, mannitol, glycerol, and polyethylene glycols (PEGs).
  • the carbohydrates such as mannose, ribose, sucrose, fructose, trehalose, maltose, inositol, and lactose, on the other hand, are cyclic molecules that may contain a keto or aldehyde group. These two classes of compounds have been demonstrated to be effective in stabilizing protein against denaturation caused by elevated temperature and by freeze-thaw or freeze-drying processes.
  • suitable carbohydrates include: galactose, arabinose, lactose or any other carbohydrate which does not have an adverse affect on a diabetic patient, i.e., the carbohydrate is not metabolized to form unacceptably large concentrations of glucose in the blood.
  • Such carbohydrates are well known in the art as suitable for diabetics.
  • Sucrose and fructose are suitable for use with the compound in non-diabetic subjects.
  • the compound is stabilized with a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various PEGs of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000).
  • a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various PEGs of molecular weight 200, 400, 1450, 3350, 4000, 6000, and 8000).
  • Mannitol is an example of a particular polyhydric alcohol.
  • Another useful feature of the lyophilized formulations described herein is the maintenance of the tonicity of the lyophilized formulations with the same formulation component that serves to maintain their stability. Mannitol is a particular polyhydric alcohol
  • USP United States Pharmacopeia
  • anti-microbial agents in bacteriostatic or fungistatic concentrations must be added to preparations contained in multiple dose containers. They must be present in adequate concentration at the time of use to prevent the multiplication of microorganisms inadvertently introduced into the preparation while withdrawing a portion of the contents with a hypodermic needle and syringe, or using other invasive means for delivery, such as pen injectors.
  • Anti-microbial agents should be evaluated to ensure compatibility with all other components of the formula, and their activity should be evaluated in the total formula to ensure that a particular agent that is effective in one formulation is not ineffective in another. It is not uncommon to find that a particular anti-microbial agent will be effective in one formulation but not effective in another formulation.
  • a preservative is, in the common pharmaceutical sense, a substance that prevents or inhibits microbial growth and may be added to pharmaceutical formulations for this purpose to avoid by microorganisms. 'hilst the amount of the preservative is not great, it may nevertheless affect the overall stability of the peptide.
  • the preservative for use in the pharmaceutical compositions can range from 0.005 to 1.0% (w/v), the typical range for each preservative, alone or in combination with others, is: benzyl alcohol (0.1-1.0%), or m-cresol (0.1-0.6%), or phenol (0.1-0.8%) or combination of methyl (0.05-0.25%) and ethyl- or propyl- or butyl- (0.005%-0.03%) parabens.
  • the parabens are lower alkyl esters of para-hydroxybenzoic acid.
  • a detailed description of each preservative is set forth in "Remington's Pharmaceutical Sciences” as well as Pharmaceutical Dosage Forms: Parenteral Medications, Vol. 1, 2nd ed., Avis et al. Ed., Mercel Dekker, New York, N. Y. (1992).
  • Pramlintide does not have a tendency to adsorb onto the glass in a glass container when in a liquid form, therefore, a surfactant is not required to further stabilize the pharmaceutical formulation.
  • a surfactant should be used in their formulation. These formulations may then be lyophilized. Surfactants frequently cause denaturation of protein, both of hydrophobic disruption and by salt bridge separation. Relatively low concentrations of surfactant may exert a potent denaturing activity, because of the strong interactions between surfactant moieties and the reactive sites on proteins.
  • Surfactants which could further stabilize the peptide may optionally be present in the range of about 0.001 to 0.3% (w/v) of the total formulation and include polysorbate 80 (i.e., polyoxyethylene(20) sorbitan monooleate), CHAPS® (i.e., 3-[(3-cholamidopropyl) dimethylammonio] 1-propanesulfonate), BRIJ® (e.g., Brij 35, which is (polyoxyethylene (23) lauryl ether), poloxamer, or another non-ionic surfactant.
  • polysorbate 80 i.e., polyoxyethylene(20) sorbitan monooleate
  • CHAPS® i.e., 3-[(3-cholamidopropyl) dimethylammonio] 1-propanesulfonate
  • BRIJ® e.g., Brij 35, which is (polyoxyethylene (23) lauryl ether), poloxamer, or another non-ionic surfactant.
  • sodium chloride or other salt may also be desirable to add sodium chloride or other salt to adjust the tonicity of the pharmaceutical formulation, depending on the tonicifier selected. However, this is optional and depends on the particular formulation selected. Parenteral formulations typically may be isotonic or substantially isotonic.
  • a suitable vehicle for parenteral products is water.
  • Water of suitable quality for parenteral administration can be prepared either by distillation or by reverse osmosis.
  • Water for injection is the preferred aqueous vehicle for use in the pharmaceutical injectable formulations.
  • additional ingredients may include, e.g., wetting agents, emulsifiers, oils, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatin or proteins) and a zwitterion (e.g., an amino acid such as betaine, taurinl?'lp ⁇ i ⁇ ' e!4 ⁇ n ⁇ l ⁇ s ⁇ il ; lnilisidine).
  • polymer solutions, or mixtures with polymers provide the opportunity for controlled release of the peptide.
  • Such additional ingredients should not adversely affect the overall stability of the pharmaceutical formulation provided herein.
  • Containers are also an integral part of the formulation of an injection and may be considered a component, for there is no container that is totally inert, or does not in some way affect the liquid it contains, particularly if the liquid is aqueous. Therefore, the selection of a container for a particular injection must be based on a consideration of the composition of the container, as well as of the solution, and the treatment to which it will be subjected. Adsorption of the peptide to the glass surface of the vial can also be minimized, if necessary, by use of borosilicate glass, for example, Wheaton Type I borosilicate glass #33 (Wheaton Type 1-33) or its equivalent (Wheaton Glass Co.).
  • borosilicate glass for example, Wheaton Type I borosilicate glass #33 (Wheaton Type 1-33) or its equivalent (Wheaton Glass Co.).
  • borosilicate glass vials and cartridges acceptable for manufacture include Kimbel Glass Co., West Co., Bunder Glas GMBH and Forma Vitrum.
  • the biological and chemical properties of the compound may be stabilized by formulation and lyophilization in a Wheaton Type 1-33 borosilicate serum vial to a final concentration of 0.1 mg/ml and 10 mg/ml of the compound in the presence of 5% mannitol, and 0.02% Tween 80.
  • each vial is typically sealed with a rubber stopper closure held in place by an aluminum band.
  • Stoppers for glass vials such as, West 4416/50, 4416/50 (Teflon faced) and 4406/40, Abbott 5139 or any equivalent stopper can be used as the closure for pharmaceutical for injection. These stoppers are compatible with the peptide as well as the other components of the formulation. These stoppers pass the stopper integrity test when tested using patient use patterns, e.g., the stopper can withstand at least about 100 injections.
  • the peptide can be lyophilized in vials, syringes or cartridges for subsequent reconstitution.
  • Liquid formulations provided herein can be filled into one or two chambered cartridges, or one or two chamber syringes.
  • the manufacturing process for the above liquid formulations generally involves compounding, sterile filtration and filling steps.
  • the compounding procedure involves dissolution of ingredients in a specific order (for example, preservative followed by stabilizer/tonicity agents, buffers and peptide) or dissolving at the same time.
  • [001 l4 ) f C Jk ⁇ iByM ' llfiMu ' ⁇ Iifiniiigl 1 ! non-parenteral may not require sterilization. However, if sterilization is desired or necessary, any suitable sterilization process can be used in developing the peptide pharmaceutical formulation provided herein.
  • Typical sterilization processes include filtration, steam (moist heat), dry heat, gases (e.g., ethylene oxide, formaldehyde, chlorine dioxide, propylene oxide, beta-propiolacctone, ozone, chloropicrin, peracetic acid methyl bromide and the like), exposure to a radiation source, and aseptic handling.
  • Filtration is an examplary method of sterilization for liquid formulations described herein. The sterile filtration involves filtration through 0.45 ⁇ m and 0.22 ⁇ m (1 or 2) which may be connected in series. After filtration, the solution is filled into appropriate vials or containers.
  • the liquid pharmaceutical formulations are intended for parenteral administration.
  • Suitable routes of administration include intramuscular, intravenous, subcutaneous, intradermal, intraarticular, intrathecal and the like.
  • the subcutaneous route of administration is one particular route.
  • Mucosal delivery is also particularly suitable. These mucosal routes include, but are not limited to, oral, nasal, sublingual, pulmonary and buccal routes which may include administration of the peptide in liquid, semi-solid or solid form. Administration via these routes requires substantially more peptide to obtain the desired biological effects due to decreased bioavailability compared to parenteral delivery.
  • parenteral controlled release delivery can be achieved by forming polymeric microcapsules, matrices, solutions, implants and devices and administering them parenterally or by surgical means.
  • controlled release formulations are described in U.S. Patent Nos. 6,368,630, 6,379,704, and 5,766,627, which are incorporated herein by reference. These dosage forms may have a lower bioavailability due to entrapment of some of the peptide in the polymer matrix or device. See e.g., U.S. Pat. Nos. 6,379,704, 6,379,703, and 6,296,842.
  • the compounds may be provided in dosage unit form containing an amount of the compound that will be effective in one or multiple doses to treat or help in treating the psychiatric disease and/or unwanted side effects of the psychiatric treatment/medication.
  • an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the condition to be treated, and other factors.
  • typical doses may contain from a lower limit of about 1 ⁇ g, 5 ⁇ g, 10 ⁇ g, 50 ⁇ g to 100 ⁇ g to an upper limit of about 100 ⁇ g, 500 ⁇ g, 1 mg, 5 mg, 10 mg, 50 mg or 100 mg of the pharmaceutical compound per day. Also contemplated are other dose ranges such as 0.1 ⁇ g to 1 mg of the compound per dose. Thus, exemplary doses may be 30, 60, 120, 240, or 360 ⁇ g of the compound per dose.
  • the doses per day may be delivered in discrete unit doses or provided contin ⁇ feSslf " iri " I..KUl!3ili'p ⁇ iiI#o? apportion of that 24 hour period.
  • the number of doses per day may be from 1 to about 4 doses per day, although it could be more.
  • Continuous delivery can be in the form of continuous infusions.
  • Exemplary doses and infusion rates include from 0.005 nmol/kg to about 20 nmol/kg per discrete dose or from about 0.01/pmol/kg/min to about 10 pmol/kg/min in a continuous infusion.
  • These doses and infusions can be delivered by intravenous administration (i.v.) or subcutaneous administration (s.c).
  • Exemplary total dose/delivery of the pharmaceutical composition given i.v. may be about 2 ⁇ g to about 8 mg per day, whereas total dose/delivery of the pharmaceutical composition given s.c may be about 6 ⁇ g to about 16 or 24 mg per day.
  • ALZET® osmotic pumps containing vehicle or rat amylin (300 ⁇ g/kg/d). All rats were provided with ad libitum access to standard chow, water, and a 30% sucrose drink. Subsequently, the sucrose drink was removed and half of the rats were subjected, daily, to 3 h of mild restraint stress for 3 successive days. After 3 days, sucrose was provided and its
  • Fig. IA shows that stress induced by restraint significantly increased the average sucrose to chow consumption ratio (as % of baseline) (saline, R) over control consumption without stress inducement (saline, C).
  • Fig. IA also shows that amylin administration prevents the increase in the average sucrose to chow consumption ratio expected as a result of the stress induced by restraint. Compare the sucrose to chow ratio (expressed as a percentage of baseline) between amylin- administered stress-induced rats (amylin, R) and amylin-administered non-stressed control rats (amylin, C).
  • Example 1 To confirm the interpretation of the findings outlined under Example 1, a variety of animal behavior assays were performed to test for anxiolytic, antidepressant, and antipsychotic effects of amylin administration.
  • the behavorial assays performed use art-accepted, animal models that demonstrate properties characteristic of the respective clinical condition (e.g., anxiety, depression, schizophrenia, obsessive-compulsive disorder) and hence, show face validity. These specific behavioral tests are known to be sensitive to anxiolytic, antidepressant, or antipsychotic drugs.
  • rat amylin was administered to mice at doses ranging from 0.1 to 10 mg/kg, intraperitoneally or via a subcutaneously implanted osmotic pump (ALZETO) containing vehicle or rat amylin, and their performance in the assay was assessed.
  • AZETO subcutaneously implanted osmotic pump
  • SIH stress-induced hyperthermia
  • mice were subjected to two sequential rectal temperature measurements ten minutes apart.
  • the stress from the first measurement induces hyperthermia which was measured by the second temperature measurement.
  • the difference between the two temperatures ( ⁇ T) was the stress-induced hyperthermia.
  • Results of this assay are shown in Fig. 2 where * is P ⁇ 0.05.
  • administration amylin like that of the anxiolytic positive control, chlordiazepoxide (CDP), blunted the SIH response.
  • CDP chlordiazepoxide
  • the SIH test results demonstrate the anxiolytic activity of amylin administration.
  • Amylin was also administered chronically at 300 ⁇ g/kg/d via subcutaneously implanted pumps and the animals were subjected to the SIH test. At both 1 week and 4 weeks of administration, chronic amylin infusion significantly blunted the SIH response, as did chronically infused CDP at 10 mg/kg/d.
  • the forced swim test is a commonly used paradigm to evaluate antidepressant activity of drugs. This test is based on measurement of the animal's floating time in a tank filled with water. When rats or mice are forced to swim in a deep cylinder with tepid water they become nearly immobile and cease trying to escape. This characteristic immobile posture is thought to reflect a depressive-like state and is readily influenced by a wide variety of antidepressants. See, for example, Hedou et al. (2001) Pharmacol, Biochem. Behav. 70:65-76, Chaki et al. (2003) J. Pharmacol. Exp. Ther. 304:818-826, and Porsolt et al. (1977) Nature 266:730-732.
  • Antidepressants decrease the immobility time in the FST.
  • Rat amylin or vehicle was delivered continuously for two weeks to mice by subcutaneously implanted osmotic pumps prior to the FST. On tank for a 15 minute pre-swim session. On day two, the mice were placed back into the water tank for assessment of climbing, swimming, and immobility over a 5 minute trial session. Results of the FST are shown in Fig. 4 where * is P ⁇ 0.05. As shown in Fig. 4, administration of rat amylin significantly reduced the time spent in the immobile state. Accordingly, the FST results demonstrate the antidepressant activity of amylin administration.
  • the prepulse inhibition (PPI) test measures the reflex response to externally applied auditory stimulation (acoustic startle response) and is related to the deficiency in sensory-motor gating capacity seen in schizophrenia.
  • the acoustic startle reflex is a very basic response to strong exteroceptive stimuli and is widely used to assess sensorimotor reactivity in animals and humans.
  • a weak auditory stimulus prepulse, 74 - 82 dB
  • the strong acoustic stimulus 120 dB
  • blunting of the startle response is refered to as prepulse inhibition. See, for example, Conti et al. (2005) Behavioral Neuroscience 119:1052-1060.
  • Antipsychotics increase the ability of the prepulse stimulus to blunt the startle response to the strong stimulus.
  • Some psychotomimetic agents such as phencyclidine (PCP) and ketamine, can actually reduce the percent prepulse inhibition and stimulate a psychotic-like state in animals, which can be antagonized by antipsychotic agents.
  • mice were injected with the test agent (rat amylin at 0.1, 1.0 or 10 mg/kg, or vehicle) 15 prior to the test or with haloperidol at 1 mg/kg 30 minutes prior to the test.
  • the mice were placed into an animal holder and the holder placed onto a transducer platform in an acoustic chamber.
  • a weak auditory stimulus (prepulse) of 74, 78 and 82 dB was given prior to the strong acoustic stimulus (120 dB). The amount of the animal's "reaction" to the strong stimulus was recorded.
  • Results of the PPI assay are shown in Fig. 5 where * is P ⁇ 0.05. As shown in Fig.
  • the PCP-induced locomotion test is used with the open field activity chambers and measures locomotion, rearing, and stereotypic activity under amphetamine/PCP-induced conditions.
  • the test has predictive validity for some antipsychotic drugs that normalize the hyperactivity and stereotypic behavior seen with amphetamine and PCP. See, for example, Williams et al. (2006) Prog. Neuropsychopharrnacol. Biol. Psychiatry 30:239-243.
  • Mice were injected with the test agent (rat clozapine (CZP), or vehicle) 15 - 30 minutes prior injection with 5 mg/kg PCP. The animals were then placed in the center of an open field and activity was recorded for 60 minutes. Results of this assay are shown in Fig.
  • FIG. 7A shows the increased weight gain of clozapine treated-rats compared to vehicle- treated rats.
  • Fig. 7B shows that when amylin was co-administered with clozapine, amylin prevented the weight gain observed in rats treated with clozapine alone.
  • the novel object recognition task was used to measure working memory. See, for example, Miyamoto et al. (2005) /. Neuroscience 25:1826-1835. Generally, animals spend less time exploring a previously presented object and more time exploring a novel object when both are presented together. Mice were injected IP with the test agent (rat amylin at 1.0 or 10 mg/kg, 0.1 mg/kg rolipram, or vehicle) 30 minutes prior to the training session. In the training, the mouse was allowed to explore two novel objects placed in the center of an open field. The time spent exploring each object was recorded. The objects differed in color, shape, and texture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés et des compositions pour traiter les maladies et troubles psychiatriques. Les procédés selon l'invention comprennent généralement l'administration d'une amyline ou d'un agoniste d'amyline à un sujet afin de traiter les maladies et troubles psychiatriques, et des conditions associées aux maladies et troubles psychiatriques.
EP06816288A 2006-03-31 2006-10-04 Amyline et agonistes d'amyline pour traiter les maladies et troubles psychiatriques Withdrawn EP2010208A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2006/012601 WO2006105527A2 (fr) 2005-03-31 2006-03-31 Amyline et agonistes d'amyline utiles dans le traitement des maladies et troubles psychiatriques
PCT/US2006/038919 WO2007114838A1 (fr) 2006-03-31 2006-10-04 Amyline et agonistes d'amyline pour traiter les maladies et troubles psychiatriques

Publications (1)

Publication Number Publication Date
EP2010208A1 true EP2010208A1 (fr) 2009-01-07

Family

ID=39876652

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06816288A Withdrawn EP2010208A1 (fr) 2006-03-31 2006-10-04 Amyline et agonistes d'amyline pour traiter les maladies et troubles psychiatriques

Country Status (7)

Country Link
EP (1) EP2010208A1 (fr)
JP (1) JP2009538824A (fr)
KR (1) KR20080106950A (fr)
AU (1) AU2006341375B2 (fr)
CA (1) CA2647568A1 (fr)
MX (1) MX2008012666A (fr)
WO (1) WO2007114838A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100056507A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ｐｒｏ－ｇｌｙ－ｔｈｒ－ｃｙｓ－ｇｌｕ－ｉｌｅ－ｃｙｓ－ａｌａ－ｔｙｒ－ａｌａ－ａｌａ－ｃｙｓ－ｔｈｒ－ｇｌｙ－ｃｙｓ의 용도
WO2009033707A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
EP2293811A1 (fr) * 2008-06-25 2011-03-16 Novo Nordisk A/S Peptides hybrides dérivés d amyline et de calcitonine de saumon
EP2504021A4 (fr) 2009-11-23 2013-05-15 Amylin Pharmaceuticals Llc Conjugué de polypeptide
CA2813038C (fr) 2010-09-28 2021-12-28 Amylin Pharmaceuticals, Llc Leptines hautement solubles
CA2812951A1 (fr) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Polypeptides genetiquement modifies ayant une duree d'action renforcee
WO2012160212A1 (fr) 2011-05-25 2012-11-29 Camurus Ab Formulation de peptides à libération contrôlée
JP2014521594A (ja) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
US9382304B2 (en) 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity
WO2013009539A1 (fr) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Polypeptides manipulés présentant une durée d'action accrue et une immunogénicité réduite
EP3927725A4 (fr) * 2019-02-22 2023-06-14 Loyola Marymount University Variants de peptide amyloïde

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020367A1 (fr) * 1991-05-24 1992-11-26 Amylin Pharmaceuticals, Inc. Traitement de l'anorexie et des pathologies voisines
EP1888094A2 (fr) * 2005-03-31 2008-02-20 Amylin Pharmaceuticals, Inc. Amyline et agonistes d'amyline utiles dans le traitement des maladies et troubles psychiatriques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO2005081619A2 (fr) * 2003-11-20 2005-09-09 Neuronova Ab Composes et procedes pour accroitre la neurogenese
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020367A1 (fr) * 1991-05-24 1992-11-26 Amylin Pharmaceuticals, Inc. Traitement de l'anorexie et des pathologies voisines
EP1888094A2 (fr) * 2005-03-31 2008-02-20 Amylin Pharmaceuticals, Inc. Amyline et agonistes d'amyline utiles dans le traitement des maladies et troubles psychiatriques
EP2135617A2 (fr) * 2005-03-31 2009-12-23 Amylin Pharmaceuticals, Inc. Amyline et agonistes d'amyline pour traiter les maladies et les troubles psychiatriques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FLOOD J F ET AL: "Differential effects of amylin on memory processing using peripheral and central routes of administration", PEPTIDES, ELSEVIER, AMSTERDAM, vol. 13, no. 3, 1 May 1992 (1992-05-01), pages 577 - 580, XP024345943, ISSN: 0196-9781, [retrieved on 19920501], DOI: 10.1016/0196-9781(92)90092-H *
R. O'CARROLL: "Cognitive impairment in schizophrenia", ADVANCES IN PSYCHIATRIC TREATMENT, vol. 6, no. 3, 1 May 2000 (2000-05-01), pages 161 - 168, XP055048308, ISSN: 1355-5146, DOI: 10.1192/apt.6.3.161 *
See also references of WO2007114838A1 *

Also Published As

Publication number Publication date
JP2009538824A (ja) 2009-11-12
WO2007114838A1 (fr) 2007-10-11
KR20080106950A (ko) 2008-12-09
AU2006341375B2 (en) 2013-03-21
AU2006341375A1 (en) 2007-10-11
AU2006341375A2 (en) 2009-09-24
CA2647568A1 (fr) 2007-10-11
MX2008012666A (es) 2008-10-13

Similar Documents

Publication Publication Date Title
US7671023B2 (en) Amylin agonist for treating depression, anxiety disorder and schizophrenia
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
ES2309108T3 (es) Tratamiento de enfermedades neurologicas y neuropsicologicas.
US7485620B2 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US8071368B2 (en) Methods for promoting growth and survival of insulin-secreting cells
US20130035294A1 (en) Neuromedin and FN-38 Peptides for Psychotic Diseases
US20090181890A1 (en) Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
US20070275877A1 (en) Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
CA3212248A1 (fr) Methodes ameliorees de traitement de maladies dues a une reponse au stress inadaptee
CN101208098A (zh) 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081024

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20101228

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMYLIN PHARMACEUTICALS, LLC

Owner name: ASTRAZENECA PHARMACEUTICALS LP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130528